Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial.
Claassens DMF, van Dorst PWM, Vos GJA, Bergmeijer TO, Hermanides RS, van 't Hof AWJ, van der Harst P, Barbato E, Morisco C, Tjon Joe Gin RM, Asselbergs FW, Mosterd A, Herrman JR, Dewilde WJM, Postma MJ, Deneer VHM, Ten Berg JM, Boersma C. Claassens DMF, et al. Among authors: hermanides rs. Am J Cardiovasc Drugs. 2022 Mar;22(2):195-206. doi: 10.1007/s40256-021-00496-4. Epub 2021 Sep 7. Am J Cardiovasc Drugs. 2022. PMID: 34490590
High-dose tirofiban pretreatment reduces the need for bail-out study medication in patients with ST-segment elevation myocardial infarction: results of a subgroup analysis of the On-TIME 2 trial.
Hermanides RS, Heestermans AA, Ten Berg JM, Gosselink AT, Ottervanger JP, van Houwelingen KG, Kolkman JJ, Stella PR, Dill T, Hamm C, van 't Hof AW. Hermanides RS, et al. Heart. 2011 Jan;97(2):106-11. doi: 10.1136/hrt.2010.194951. Epub 2010 Oct 20. Heart. 2011. PMID: 20962338 Clinical Trial.
A comparison between upfront high-dose tirofiban versus provisional use in the real-world of non-selected STEMI patients undergoing primary PCI: Insights from the Zwolle acute myocardial infarction registry.
Heestermans AA, Hermanides RS, Gosselink AT, de Boer MJ, Hoorntje JC, Suryapranata H, Ottervanger JP, Dambrink JH, Kolkman E, Ten Berg JM, Zijlstra F, van 't Hof AW. Heestermans AA, et al. Among authors: hermanides rs. Neth Heart J. 2010 Dec;18(12):592-7. doi: 10.1007/s12471-010-0840-z. Neth Heart J. 2010. PMID: 21301621 Free PMC article.
The impact of age on effects of pre-hospital initiation of high bolus dose of tirofiban before primary angioplasty for ST-elevation myocardial infarction.
Hermanides RS, van Houwelingen G, Ottervanger JP, de Boer MJ, Dill T, Hamm C, Stella PR, Boersma E, ten Berg JM, van 't Hof AW; On-TIME 2 trial investigators. Hermanides RS, et al. Cardiovasc Drugs Ther. 2011 Aug;25(4):323-30. doi: 10.1007/s10557-011-6314-8. Cardiovasc Drugs Ther. 2011. PMID: 21744314 Clinical Trial.
The effect of pre-hospital glycoprotein IIb-IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI.
Hermanides RS, van Werkum JW, Ottervanger JP, Breet NJ, Gosselink AT, van Houwelingen KG, Dambrink JH, Hamm C, ten Berg JM, van 't Hof AW; Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group. Hermanides RS, et al. Catheter Cardiovasc Interv. 2012 May 1;79(6):956-64. doi: 10.1002/ccd.23165. Epub 2011 Dec 12. Catheter Cardiovasc Interv. 2012. PMID: 22162050 Clinical Trial.
Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score.
Hermanides RS, Ottervanger JP, ten Berg JM, Gosselink AT, van Houwelingen G, Dambrink JH, Stella PR, Hamm C, van 't Hof AW; On-TIME 2 Trial Investigators. Hermanides RS, et al. J Invasive Cardiol. 2012 Mar;24(3):84-9. J Invasive Cardiol. 2012. PMID: 22388296 Free article. Clinical Trial.
98 results